Proposing essential medicines to treat cancer: Methodologies, processes, and outcomes

Journal of Clinical Oncology

Volumn 34, Issue 1, 2016, Pages 69-75

  Shulman, Lawrence N ^a   Wagner, Claire M ^a   Barr, Ronald ^a   Lopes, Gilberto ^a   Longo, Giuseppe ^a   Robertson, Jane ^a   Forte, Gilles ^a   Torode, Julie ^a   Magrini, Nicola ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANASTROZOLE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; BENDAMUSTINE; BICALUTAMIDE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; HYDROCORTISONE; RETINOIC ACID; UNINDEXED DRUG; ESSENTIAL DRUG;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER THERAPY; GOVERNMENT; HEALTH CARE COST; HUMAN; MEDICAL EXPERT; PATIENT CARE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; NEOPLASMS;

DRUGS, ESSENTIAL; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84954184520     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.8736     Document Type: Review

References (58)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Farmer P, Frenk J, Knaul FM, et al: Expansion of cancer care and control in countries of low and middle income: A call to action. Lancet 376: 1186-1193, 2010
3. DeVita VT, Chu E: A history of cancer chemotherapy. Cancer Res 68:8643-8653, 2008
4. Devita VT Jr, Rosenberg SA: Two hundred years of cancer research. N Engl JMed 366:2207-2214, 2012
5. American Cancer Society. The history of cancer, update 2014. http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/index#
6. Efstathiou JA, Bvochora-Nsingo M, Gierga DP, et al: Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership. Int J Radiat Oncol Biol Phys 89:468-475, 2014
7. Ribeiro RC: Improving survival of children with cancer worldwide: The St Jude International Outreach Program approach. Stud Health Technol Inform 172:9-13, 2012
8. Strother RM, Asirwa FC, Busakhala NB, et al: AMPATH oncology: A model for comprehensive cancer care in sub-Saharan Africa. J Cancer Policy 1: e42-e48, 2013
9. Kingham TP, Alatise OI, Vanderpuye V, et al: Treatment of cancer in sub-Saharan Africa. Lancet Oncol 14:e158-e167, 2014
10. Israels T, Borgstein E, Pidini D, et al:Management of children with a Wilms tumor in Malawi, sub-Saharan Africa. J Pediatr Hematol Oncol 34:606-610, 2012
11. Moreira C, Nachef MN, Ziamati S, et al: Treatment of nephroblastoma in Africa: Results of the first French African Pediatric Oncology Group (GFAOP) study. Pediatr Blood Cancer 58:37-42, 2012
12. Adesina A, Chumba D, Nelson AM, et al: Improvement of pathology in sub-Saharan Africa. Lancet Oncol 14:e152-e157, 2013
13. Informal Working Group on Cancer Treatment in Developing Countries (CanTreat International): Access to cancer treatment in low-and middleincome countries: An essential part of global cancer control, 2006. http://axios-group.com/assets/Uploads/CanTreat-UICC-IssuePaper-2010.pdf
14. Adewole I, Martin DN, Williams MJ, et al: Building capacity for sustainable research programmes for cancer in Africa. Nat Rev Clin Oncol 11: 251-259, 2014
15. [No authors listed]: Access to cancer medicine in low-resource settings. Lancet Oncol 14:1, 2013
16. Bazargani YT, de Boer A, Schellens JHM, et al: Selection of oncology medicines in low-and middleincome countries. Ann Oncol 25:270-276, 2014
17. Bollyky TJ: Access to drugs for treatment of noncommunicable diseases. PLoS Medicine 10: e1001485, 2013
18. Coleman MP: Cancer survival: Global surveillance will stimulate health policy and improve equity. Lancet 383:564-573, 2014
19. Hogerzeil HV, Liberman J, Wirtz VJ, et al: Promotion of access to essential medicines for noncommunicable diseases: Practical implications of the UN political declaration. Lancet 381:680-689, 2013
20. Lopes Gde L Jr, de Souza JA, Barrios C: Access to cancer medications in low-and middle-income countries. Nat Rev Clin Oncol 10:314-322, 2013
21. Cavalli F, Atun R: Towards a global cancer fund. Lancet Oncol 16:133-134, 2015
22. Mehta PS, Wiernikowski JT, Petrilli JAS, et al: Essential medicines for pediatric oncology in developing countries. Pediatr Blood Cancer 60:889-891, 2013
23. Sullivan R, Kowalczyk JR, Agarwal B, et al: New policies to address the global burden of childhood cancers. Lancet Oncol 14:e12-e135, 2013
24. WHO: Model List of Essential Medicines for Adults (18th list). Geneva, Switzerland, WHO, 2013
25. WHO: Model List of Essential Medicines for Children (4th list). Geneva, Switzerland, WHO, 2013
26. WHO: WHO Model Lists of Essential Medicines, 2013 update. http://www.who.int/medicines/publications/essentialmedicines/en/index.html
27. Laing R, Waning B, Gray A, et al: 25 years of the WHO essential medicines lists: Progress and challenges. Lancet 361:1723-1729, 2003
28. Hansen HH, Henderson IC, Hoth D, et al: Essential drugs for cancer chemotherapy: Memorandum from a WHO meeting. Bull World Health Org 63:999-1002, 1985
29. Advani S, Friedman MA, Henderson IC, et al: Essential drugs for cancer chemotherapy: WHO consultation. BullWorld Health Org 72:693-698, 1994
30. Sikora K, Advani S, Koroltchouk V, et al: Essential drugs for cancer therapy: A World Health Organization consultation. Ann Oncol 10:385-390, 1999
31. WHO: Union for International Cancer Control list of contributors, 2014 review of cancer medicines on theWHOList of Essential Medicines. http://www. who.int/selection-medicines/committees/expert/20/applications/UICC-EMLreview-contributors-Final-2014.pdf?ua51
32. Allemani C, Weir HK, Carreira H, et al: Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 385:977-1010, 2014
33. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer Res 136:E359-E386, 2015
34. Goldstraw P, Ball D, Jett JR, et al: Non-smallcell lung cancer. Lancet 378:1727-1740, 2011
35. Hehlmann R, Hochhaus A, BaccaraniM: Chronic myeloid leukemia. Lancet 370:342-350, 2007
36. Institute for Health Metrics and Evaluation: Global Burden of Disease Study 2010 (GBD 2010) results by risk factor, 1990-2010. Seattle, WA, Institute for Health Metrics and Evaluation, 2012
37. Pfreundschuh M, Kuhnt E, Tru'mper L, et al: CHOP-like chemotherapy with or without rituximab in young patientswith good-prognosis diffuse large-B-cell lymphoma: 6-Year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013-1022, 2011
38. Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 379:432-444, 2012
39. Burstein HJ, Temin S, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255-2269, 2014
40. Ries L, Eisner M, Kosary C, et al (eds): SEER cancer statistics review, 1975-2002. Bethesda, MD National Cancer Institute, 2005
41. American Cancer Society. Cancer treatment and survivorship fact and figures 2012-2013. Atlanta, GA, American Cancer Society.
42. Lim E, Harris G, Patel A, et al: Preoperative versus postoperative chemotherapy in patients with resectable non-small-cell lung cancer: Systematic review and indirect comparison with metaanalysis of randomised trials. J Thorac Oncol 4: 1380-1388, 2009
43. NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomised controlled trials. J Clin Oncol 26:4617-4625, 2008
44. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
45. Garassino MC, Martelli O, Broggini M, et al: Erlotinib versus docetaxel as second-line treatment of patientswith advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial. Lancet Oncol 14:981-988, 2013
46. Lee CK, Brown C, Gralla RJ, et al: Impact of EGFR inhibitor in non-small-cell lung cancer on progression-free and overall survival: A metaanalysis. J Natl Cancer Inst 105:595-605, 2013
47. Farmer PE, Kim JY: Surgery and global health: A view from beyond the OR. World J Surg 32: 533-536, 2008
48. Gyorki DE, Muyco A, Kushner AL, et al: Cancer surgery in low-income countries: An unmet need. Arch Surg, 147:1135-1140, 2012
49. Ilbawi AM, Einterz EM, Nkusu D: Financial obstacles to surgical care in low income country district hospital. World J Surg 37:1208-1215, 2013
50. Anderson BO, Ilbawi AM, El Saghir NS: Breast cancer in low and middle income countries: A shifting tide in global health. Breast J 21:111-118, 2015
51. American Cancer Society: Cervical cancer: Treatment options for cervical cancer, by stage, update 2015. http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-treating-by-stage
52. Bloch EM, Vermeulen M, Murphy E: Blood transfusion safety in Africa: A literature review of infectious disease and organizational challenges. Transfus Med Rev 26:164-180, 2012
53. Chalkidou K, Marquez P, Dhillon PK, et al: Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and highincome countries. Lancet Oncol 15:e119-e131, 2014
54. Kerr DJ, Midgley R: Can we treat cancer for a dollar a day? Guidelines for low-income countries. N Engl J Med 363:801-803, 2010
55. Renner L, Nkansah FA, Dodoo ANO: The role of generic medicines and biosimilars in oncology in low-income countries. Ann Oncol 24:v29-v32, 2013 (suppl 5)
56. Tagar E, Sundaram M, Condliffe K, et al: Multicountry analysis of treatment costs for HIV/AIDS (MATCH): Facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa, and Zambia. PloS ONE 9:e108304, 2014
57. Gupta R, Kim JY, Espinal MA, et al: Responding to market failures in tuberculosis control. Science 293:1049-1051, 2001
58. Holmes CB, CogginW, Jamieson D, et al: Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 304:313-320, 2010